PLSE News & Events

Pulse Biosciences announced late-breaking "positive" clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. Key study findings on the 5 second ablation cohort include: Sustained 100% procedural success of evaluable patients by holter at 6 months; Sustained 96% procedural success of evaluable patients by holter at one year; Sustained 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year; Consistently efficient procedural performance, including: Left atrial dwell time: 18.6 +/- 13.0 minutes, Total procedure time: 60.2 +/- 27.7 minutes, Fluoroscopy time: 9.4 +/- 5.9 minutes, Average applications per-patient for PVI: 12.3 +/- 2.6; Safety profile across total cohort: maintained low serious adverse event rate, with 1.7% of subjects experiencing a SAE related to the primary safety endpoint

Pulse Biosciences announced late-breaking positive clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. Key study findings on the 5 second ablation cohort include: Sustained 100% procedural success of evaluable patients by holter at 6 months; Sustained 96% procedural success of evaluable patients by holter at one year; Sustained 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year; Consistently efficient procedural performance, including: Left atrial dwell time: 18.6 +/- 13.0 minutes, Total procedure time: 60.2 +/- 27.7 minutes, Fluoroscopy time: 9.4 +/- 5.9 minutes, Average applications per-patient for PVI: 12.3 +/- 2.6; Safety profile across total cohort: maintained low serious adverse event rate, with 1.7% of subjects experiencing a SAE related to the primary safety endpoint

Pulse Biosciences announced the strengthening of its executive leadership team with the appointment of Liane Teplitsky as Chief Operating Officer and expanded role of Dr. David Kenigsberg as full-time Chief Medical Officer. Both the appointment of Liane Teplitsky as Chief Operating Officer and Dr. David Kenigsberg's agreement to serve as the Company's Chief Medical Officer on a full-time basis further enhance the Company's strategic alignment to prioritize and accelerate the development and future commercialization of its nPulse Cardiac Catheter Ablation System. As COO, Teplitsky will oversee the Company's Clinical, Regulatory, Quality, and Commercial functions. Teplitsky most recently served as Chief Executive Officer of Artedrone. The Company also announced that David Kenigsberg, MD, FACC, FHRS, Chief Medical Officer of Pulse Biosciences, will expand his role, while maintaining his active routine clinical practice. His increased leadership capacity will benefit the Company as it advances its IDE pivotal clinical study evaluating the nPulse Cardiac Catheter System for the treatment of atrial fibrillation.